Assessing the reporting quality of early phase dose-finding trials

被引：7
|
作者：
Yap, C. [1 ]
Solovyeva, O. [2 ]
Yin, Z. [2 ]
Martin, J. [3 ]
Manickavasagar, T. [3 ]
Weir, C. [4 ]
Lee, S. [5 ]
Dimairo, M. [6 ]
Liu, R. [7 ]
Kightley, A. [8 ]
de Bono, J. S. [9 ]
机构：
[1] ICR Inst Canc Res, Clin Trials Biostat Dept, North Site, London, England
[2] Inst Canc Res, Clin Trials & Stat Unit, London, England
[3] Inst Canc Res, Drug Dev Unit, London, England
[4] Univ Edinburgh, Edinburgh Clin Trials Unit, Edinburgh, Midlothian, Scotland
[5] Columbia Univ, Irving Med Ctr, New York, NY USA
[6] Univ Sheffield, Clin Trials Res Unit, Sheffield, S Yorkshire, England
[7] Bristol Meyers Squibb, Oncol, New York, NY USA
[8] Patient & Publ Involvement Partner, Lichfield, England
[9] ICR Inst Canc Res, Drug Dev Unit, London, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
53P
引用
收藏
页码：S24 / S24
页数：1
相关论文
共 50 条
  • [41] Implementation of adaptive dose-finding designs in two early phase haematological trials: clinical, operational, and methodological challenges
    Christina Yap
    Charlie Craddock
    Graham Collins
    Josephine Khan
    Shamyla Siddique
    Lucinda Billingham
    Trials, 14 (Suppl 1)
  • [42] Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study
    Olga Solovyeva
    Munyaradzi Dimairo
    Christopher J. Weir
    Siew Wan Hee
    Aude Espinasse
    Moreno Ursino
    Dhrusti Patel
    Andrew Kightley
    Sarah Hughes
    Thomas Jaki
    Adrian Mander
    Thomas R. Jeffry Evans
    Shing Lee
    Sally Hopewell
    Khadija Rerhou Rantell
    An-Wen Chan
    Alun Bedding
    Richard Stephens
    Dawn Richards
    Lesley Roberts
    John Kirkpatrick
    Johann de Bono
    Christina Yap
    BMC Medicine, 21
  • [43] A robust Bayesian dose-finding design for phase I/II clinical trials
    Liu, Suyu
    Johnson, Valen E.
    BIOSTATISTICS, 2016, 17 (02) : 249 - 263
  • [44] Bayesian Sample Size Planning Tool for Phase I Dose-Finding Trials
    Lin, Xiaolei
    Lyu, Jiaying
    Yuan, Shijie
    Bi, Dehua
    Wang, Sue-Jane
    Ji, Yuan
    JCO PRECISION ONCOLOGY, 2022, 6
  • [45] Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes
    Resche-Rigon, Matthieu
    Zohar, Sarah
    Chevret, Sylvie
    CLINICAL TRIALS, 2008, 5 (06) : 595 - 606
  • [46] Design Issues in Dose-Finding Phase I Trials for Combinations of Two Agents
    Fan, Shenghua Kelly
    Venook, Alan P.
    Lu, Ying
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2009, 19 (03) : 509 - 523
  • [47] Innovations for phase I dose-finding designs in pediatric oncology clinical trials
    Doussau, Adelaide
    Geoerger, Birgit
    Jimenez, Irene
    Paoletti, Xavier
    CONTEMPORARY CLINICAL TRIALS, 2016, 47 : 217 - 227
  • [48] REEVALUATION OF DECISIONS ON THE RECOMMENDED DOSE FROM PHASE-III DOSE-FINDING TRIALS - DISCUSSION
    MAURER, W
    WHITEHEAD, J
    ROHMEL, J
    DERZKO, G
    HUCHER, M
    BAUER, P
    STATISTICS IN MEDICINE, 1995, 14 (9-10) : 897 - 899
  • [49] Let's make poor reporting of early phase dose finding clinical trials a thing of the past
    Yap, Christina
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 383
  • [50] A multiple comparison procedure for dose-finding trials with subpopulations
    Thomas, Marius
    Bornkamp, Bjoern
    Posch, Martin
    Koenig, Franz
    BIOMETRICAL JOURNAL, 2020, 62 (01) : 53 - 68
12345